Stock Financial Ratios


AGIO / Agios Pharmaceuticals, Inc. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Price69.89
Volume4,119,600.00
Market Cap ($M)3,408.15
Enterprise Value ($M)2,472.97
Book Value ($M)358.59
Book Value / Share9.16
Price / Book7.34
NCAV ($M)530.66
NCAV / Share13.56
Price / NCAV11.64
Income Statement (mra) ($M)
Revenue0.00
EBITDA-200.99
Net Income-198.47
Balance Sheet (mrq) ($M)
Cash & Equivalents132.74
Cash / Share3.39
Assets687.20
Liabilities237.39
Quick Ratio6.33
Current Ratio6.33
Management Effectiveness (mra)
Return on Invested Capital (ROIC)-0.55
Return on Assets (ROA)-0.32
Return on Equity (ROE)-0.55
Identifiers and Descriptors
CUSIP00847X104
Central Index Key (CIK)1439222
Industry Groups
SIC 2834 - Pharmaceutical Preparations
Other Related CUSIPS
00847X904
00847X954
Share Statistics
Common Shares Outstanding (M)48.75
Scoring Models
Piotroski F Score3.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Kaplan-Zingales KZ-IndexN/A
Cash Conversion CycleN/A
Per Share Metrics
Assets Other Non Current Per Share0.03
Retained Earnings Per Share-18.14
Liabilities Per Share6.07
Accumulated Depreciation And Depletion Per Share0.00
Property Plant And Equipment Net Per Share0.61
Minority Interest Per Share0.00
Inventory Work In Progress Per Share0.00
Long Term Debt Per Share0.00
Treasury Stock Per Share0.00
Assets Per Share17.56
Debt Per Share0.00
Inventory Per Share0.00
Cash And Equivalents Per Share3.39
Additional Paid In Capital Per Share29.65
Equity Per Share11.50
Intangibles Per Share0.00
Goodwill Per Share0.00
Property Plant And Equipment Per Share0.61
Liabilities Current Per Share2.25
Deferred Income Tax Liabilities Per Share0.00
Current Portion Of Long Term Debt Per Share0.00
Assets Current Per Share13.50
Property Plant And Equipment Gross Per Share0.00
Liabilities And Stock Equity Per Share17.56
Accounts Receivable Per Share0.00
Inventory Raw Materials Per Share0.00
Cash Per Share3.39
Assets Other Current Per Share0.00
Accounts Payable Per Share0.00
Inventory Finished Goods Per Share0.00
Liabilities Other Non Current Per Share0.00
Preferred Stock Value Outstanding Per Share0.00
Assets Non Current Per Share0.00

Related News Stories

Your Daily Pharma Scoop: Ablynx Takeover Battle, Acorda Takeover Speculation, Oramed Update

2018-01-20 seekingalpha
Today, we will discuss the ongoing takeover battle involving Novo Nordisk (NVO) and Belgian biotech Ablynx. (307-2)

Agios sizes up funding needs

2018-01-19 reuters
Jan 19 (IFR) - Agios Pharmaceuticals pivoted from industry conferences to the capital markets, securing US$425m in a follow-on stock sale that meets its funding needs for the year. (9-0)

Here's Why Agios (AGIO) Stock is Up More Than 50% in a Year

2018-01-19 zacks
Shares of Agios Pharmaceuticals, Inc. (AGIO - Free Report) have soared 60.7% in a year’s time, outperforming the industry's increase of 25.1%. (98-0)

BRIEF-Agios prices offering of 7.09 mln shares at $67 per share

2018-01-19 reuters
* AGIOS PHARMACEUTICALS - ‍IT HAS PRICED AN UNDERWRITTEN PUBLIC OFFERING OF 7.09 MILLION SHARES OF COMMON STOCK AT A PRICE TO PUBLIC OF $67.00 PER SHARE​ Source text for Eikon: Further company coverage: (9-0)

Celgene Provides 2017 Preliminary Results & 2018 View

2018-01-09 zacks
Celgene Corporation (CELG - Free Report) provided preliminary results for 2017 and guidance for 2018 at the 36th Annual J.P. Morgan Healthcare Conference. (82-0)

CUSIP: 00847X104